Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program

- Announced VG-3927 as lead candidate to enter clinical development for potential treatment of Alzheimer’s Disease -

Related Keywords

,Marco Colonna ,Megan Mcgrath ,Samuele Gandy ,Leah Gibson ,Exchange Commission ,Mount Sinai Alzheimer Disease Research Center ,Vigil Neuroscience Inc ,Drug Administration ,Nasdaq ,Company Phase ,Washington University School Of Medicine ,Investor Relations Corporate Communications ,Mount Sinai Professor Of Alzheimer Disease Research ,Investigational New Drug ,Robert Rock Belliveau Professor ,Washington University School ,Mount Sinai Professor ,Disease Research ,Associate Director ,Mount Sinai Alzheimer ,Past Chairman ,National Medical ,Scientific Advisory Council ,Vigil Neuroscience ,Quarterly Report ,Investor Relations ,Region ,